HC Wainwright & Co. Initiates Coverage On Eikon Therapeutics with Buy Rating, Announces Price Target of $23

HC Wainwright & Co. analyst Sara Nik has initiated coverage on Eikon Therapeutics (NASDAQ: EIKN) with a Buy rating. The firm has set a price target of $23 for the stock.